Brian Levy

Company: InflammX Therapeutics

Job title: Chief Executive Officer

Seminars:

Using an Oral Anti-Inflammatory Drug to Improve Treatment Options for DME & DR Patients Non-Responsive to Anti-VEGF Therapy 9:30 am

Addressing the unmet need in DR and DME patients receiving anti-VEGF treatment by targeting non-responders with Xiflam, a once-daily oral small molecule that inhibits the pathologically open Connexin43 (Cx43) hemichannel Demonstrating positive preclinical results, Xiflam shows promise in modulating the dysregulated inflammasome pathway, reducing autoinflammation in DME and DR Exploring the benefits of oral administration…Read more

day: Day Two